The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Ferring
Stock and Other Ownership Interests - Ferring
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Rian Dickstein
Employment - Chesapeake Urology
Honoraria - UroGPO
Consulting or Advisory Role - CG Oncology; Ferring; Johnson & Johnson/Janssen; Olympus; Photocure; Urogen pharma
Speakers' Bureau - Ferring; Urogen pharma
 
Mark Tyson
Consulting or Advisory Role - AstraZeneca; enGene; ImmunityBio
Research Funding - AstraZeneca (Inst); CG Oncology (Inst); enGene (Inst); Ferring (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); NCI (Inst); pacific edge (Inst); Protara Therapeutics (Inst); Seagen (Inst); SWOG (Inst); Urogen pharma (Inst)
 
Vikram Narayan
Consulting or Advisory Role - Ciox Health; Ferring Pharmaceuticals Inc
Research Funding - Ciox Health; Ferring Pharmaceuticals Inc
 
Gautum Agarwal
Consulting or Advisory Role - Signatera
 
Evan Goldfischer
No Relationships to Disclose
 
Michael Williams
Consulting or Advisory Role - Ferring Pharmaceuticals Inc; Foundation Medicine
Speakers' Bureau - Astellas Medivation; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); FerGene (Inst); Ferring Pharmaceuticals Inc (Inst); Genomic Health (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
 
Corine Baayen
Employment - Ferring
Stock and Other Ownership Interests - Ferring
 
Kristian Juul
Employment - Ferring
Stock and Other Ownership Interests - Ferring
 
Per Sandstrom
No Relationships to Disclose
 
Trinity Bivalacqua
Consulting or Advisory Role - CG Oncology; Ferring Pharmaceuticals Inc; UroGen pharma
Research Funding - CG Oncology; Ferring Pharmaceuticals Inc; UroGen pharma